ÌÇÐÄvlogÃÛÌÒ

Changyi Johnny Chen

Chen

Changyi Johnny Chen, M.D., Ph.D.

Professor and Director, Basic Science and Translational Labs

(713) 798-4401

Positions

Professor and Director, Basic Science and Translational Labs
ÌÇÐÄvlogÃÛÌÒ of Medicine
Molecular Surgery Endowed Chair
ÌÇÐÄvlogÃÛÌÒ of Medicine
Professor of Molecular and Cellular Biology
ÌÇÐÄvlogÃÛÌÒ of Medicine
Editor-in-Chief
Patient Preference and Adherence

Addresses

Alkek Building for Biomedical Research (Lab)
One Baylor Plaza
R413
Houston, TX, 77021
United States

Education

PhD from Georgia Institute of Technology
01/1996 - Atlanta, GA, United States
MS from The University of Texas at El Paso
01/1991 - El Paso, TX, United States
Residency at Southeast University School of Medicine - Zhong-Da Hospital
01/1987 - Nanjing, China, People's Rep
MD from Southeast University School of Medicine
01/1982 - Nanjing, China, People's Rep

Honors & Awards

2018 Hans-Peter Krayenbuehl Memorial Award
International Academy of Cardiology
Inaugural Senior Member
National Academy of Inventors (NAI)

Professional Interests

  • Pancreatic cancer
  • Hyperuricemia and uric acid-lowering drug discoveries
  • LGA-PEI based nanotechnology drug delivery systems
  • Pancreatic cancer
  • ACE2 inhibitors and drug discoveries
  • Endothelial dysfunction and vascular disease
  • Angiogenesis
  • Atherosclerosis
  • Cardiovascular disease
  • Endothelial nitric oxide synthase
  • Hemodynamics
  • Vascular tissue engineering
  • Oxidative stress and antioxidants

Professional Statement

Dr. Chen's laboratory is actively conducting several basic science and translational research projects that are highly relevant to clinical cardiovascular disease and pancreatic cancer.
Cardiovascular risk factors and their molecular mechanisms in cardiovascular disease:
We are investigating the effects and the molecular mechanisms of several cardiovascular risk factors, including HIV protease inhibitors, the adipokine resistin, soluble CD40L, and uric acid, on biochemical pathways associated with endothelial cell functions. Some of the biochemical pathways under investigation are the endothelial nitric oxide synthase system, the oxidative stress system, and signal transduction pathways. We are carrying on these investigations using several experimental models, such as myographies, organ cultures, mouse models, human tissue samples, and different types of endothelial cells. Based on the molecular mechanisms we uncover, we develop effective therapeutic strategies to treat endothelial dysfunction and atherosclerosis.
Endothelial cell differentiation and angiogenesis:
We are studying the role played by and the molecular mechanisms of hemodynamic factors and several novel molecules on endothelial cells differentiated from embryonic stem cells and from bone marrow-derived stem cells. We are identifying key regulatory genes that trigger endothelial cell differentiation and promote stable angiogenesis. These findings can potentially be applied to the design of novel therapeutic strategies to treat ischemic tissues using genetically engineered endothelial cells. In addition, these studies may provide useful information to genetically engineer novel tissues for vascular grafts.
Pancreatic cancer:
We have been heavily involved in pancreatic cancer research programs for many years. We have several projects focusing on the role and on the mechanisms of several genes, such as microRNA 196a (miR-196a), X-inactive specific transcript (XIST), and Jude-2 in pancreatic cancer. Our comprehensive studies analyze human cancer specimens, clinical outcomes, established cell lines, a nude mouse model, and a genetically engineered mouse model of pancreatic cancer called the KPC model. We are developing LGA-PEI-based nanotechnology for molecular imaging and for specific drug and gene delivery, which has great potential clinical applications, such as molecular diagnostics and targeted therapies.
Drug discoveries:
We have been actively involved in drug discovery programs through high throughput screen libraries, focusing on novel xanthine oxidase (XO) inhibitors, which have potential clinical applications for the treatment of hyperuricemia-associated diseases. Recently, we also discover novel ACE2 inhibitors, which may have potential clinical application for the prevention or treatment of COVID-19 or other ACE2 related diseases.

Websites

eNOS Signal Pathways
ÌÇÐÄvlogÃÛÌÒ of Medicine graduate starts Speratum CR to bring his own discovery to cancer patients

Videos

eNOS Signaling Pathways

Selected Publications

  • Mohiuddin I, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. " " J. Surg. Res.. 2006 Jun 15; 133 (2) : 143-9.
    Pubmed PMID: .
  • Conklin BS, Zhong DS, Zhao W, Lin PH, Chen C. " " J. Surg. Res.. 2002 Jan ; 102 (1) : 13-21.
    Pubmed PMID: .
  • Yan S, Li M, Chai H, Yang H, Lin PH, Yao Q, Chen C. " " J. Surg. Res.. 2005 Feb ; 123 (2) : 294-301.
    Pubmed PMID: .
  • Li M, Fisher WE, Kim HJ, Wang X, Brunicardi CF, Chen C, Yao Q. " " World J Surg. 2005 Mar ; 29 (3) : 293-6.
    Pubmed PMID: .

to edit your profile